Aclarion, Inc. (ACON) NASDAQ
3.32
+0.06(+1.84%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.32
+0.06(+1.84%)
Currency In USD
| Previous Close | 3.26 |
| Open | 3.3 |
| Day High | 3.45 |
| Day Low | 3.24 |
| 52-Week High | 12.03 |
| 52-Week Low | 2.34 |
| Volume | 61,827 |
| Average Volume | 105,903 |
| Market Cap | 1.77M |
| PE | -0.24 |
| EPS | -13.61 |
| Moving Average 50 Days | 3.2 |
| Moving Average 200 Days | 5.63 |
| Change | 0.06 |
Aclarion Publishes 2026 Shareholder Letter from the Chairman
GlobeNewswire Inc.
Feb 05, 2026 11:00 AM GMT
Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion”
Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
GlobeNewswire Inc.
Feb 03, 2026 11:00 AM GMT
Expands availability of Nociscan in the greater Los Angeles areaReinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedureSupports scalable growth strategy while b
Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
GlobeNewswire Inc.
Jan 13, 2026 11:00 AM GMT
Debt-Free Balance Sheet With $21.6 Million in CashBROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarke